Successful treatment of T-gamma lymphoproliferative disease with human-recombinant granulocyte colony stimulating factor.
A trial of recombinant human granulocyte colony-stimulating factor (rhG-CSF) was attempted in a male with agranulocytosis, infection, and T-gamma lymphoproliferative disease (T-gamma-LPD). During five days of rhG-CSF (960 micrograms/day), the absolute neutrophil count (ANC) increased from 0.0 to 4.5 K/microliters. There were no changes in eosinophil or lymphocyte counts. In addition, there was no toxicity. Bone marrow cytotoxic/suppressor cells (CD57+/CD8+) were elevated (21.9%) before and decreased to 10.6% (normal less than 12%) following rhG-CSF. By contrast, there was no change in activated T cells (CD3+DR+) or T cell gene rearrangements. These findings suggest rhG-CSF can improve granulopoiesis in T-gamma-LPD, possibly by altering T-cell mediated marrow suppression.
Lang
D F
DF
Western Pennsylvania Cancer Inst., West Penn Hospital, Pittsburgh 15224.
Rosenfeld
C S
CS
Diamond
H S
HS
Shadduck
R K
RK
Zeigler
Z R
ZR
D000328:Adult; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D009503:Neutropenia / Q000188:drug therapy; D016692:Receptors, Antigen, T-Cell, gamma-delta; D011994:Recombinant Proteins; D016176:T-Lymphocyte Subsets
D016692:Receptors, Antigen, T-Cell, gamma-delta; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor